"Hansa Medical has made significant progress during the last period of time. We are now in a very exiting position with phase II trials of IdeS. This means that we need new competencies for the further development and commercialization of IdeS. Emanuel Björne has achieved a lot during his seven years as CEO and we are truly grateful for his efforts. Fredrik Lindgren now assumes the main responsibility for completing the development of IdeS to create a large and profitable business for Hansa Medical’s shareholders." says Birgit Stattin Norinder, Chairman of the Board.

Fredrik Lindgren, born 1971, has significant experience from the life science sector and has led several public companies. He has been CEO of Karo Bio AB and Biolin Scientific AB, and has executive experience from Midsona AB and Active Biotech AB. Fredrik Lindgren has a law degree from Lund University and is CEFA from Stockholm School of Economics. Fredrik Lindgren owns 23 333 shares in Hansa Medical. He is currently a member of the board of ProstaLund AB and Exini Diagnostics AB. Upon assuming the position as CEO, Fredrik Lindgren will resign from the position as member of the board of Hansa Medical.